The quantitative baseline HBsAg level as a predictor for therapeutic effect among HBeAg -positive chronic hepatitis B patients treated with PEG -IFN α-2b
- VernacularTitle:基线 HBsAg 定量值预测聚乙二醇干扰素α－2b治疗慢性乙型肝炎疗效
- Author:
Ke GE
1
;
Yan-Ting BAO
;
Liang-Da ZHENG
;
Xiang ZHOU
;
Jie WANG
;
Gong-Ying CHEN
;
Guo-Qiang LOU
Author Information
1. 浙江中医药大学附属第六医院
- Keywords:
Chronic hepatitis B;
Hepatitis B surface antigen;
Baseline;
Response rate;
PEG -IFN α-2b
- From:
Journal of Preventive Medicine
2014;(11):1085-1088
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the predictive effect of baseline hepatitis B surface antigen (HBsAg)on virological response in HBeAg -positive chronic hepatitis B patients treated with pegylated interferon (PEG -IFN ) α-2b. Methods The retrospective analysis compared the treatment efficacy of PEG -IFN α-2b in 55 cases of HBeAg -positive chronic hepatitis B patients with different baseline HBsAg levels.Serum HBV DNA load was measured at baseline and after 1 2,24,and 48 weeks of the therapy.Virological response was defined as HBV DNA <1 000 IU /ml.Serum HBsAg titers were quantitatively assayed at baseline,1 2 and 24 weeks.Results 1 8 patients had baseline HBsAg levels greater than 20 000 IU /ml(Group A),26 patients had baseline HBsAg levels between 1 500 and 20 000 IU /ml(Group B)and 1 1 patients had baseline HBsAg levels less than 1 500 IU /ml(Group C)after 48 weeks treatment with PEG -IFNα-2b.The achieved virological response rates of the three groups were 1 6.67%,42.31 % and 63.64% respectively with a statistically significant difference between group A and C (P <0.05).1 3 patients had HBsAg levels declined greater than 0.5 log1 0 and 30 patients had HBsAg levels declined less than 0.5 log1 0 at week 1 2 and the achieved virological response rates were 1 6.67%,46.2% and 33.3% respectively without statistically significant difference (P >0.05).1 6 patients with HBsAg
levels greater than 20 000 IU /ml after treatment of 24 weeks did not achieve virological response after treatment of 48 weeks.Conclusion Baseline HBsAg levels in combination with HBV DNA quantitative value may become an effective predictor for guiding optimal therapy with PEG -IFN α-2b against HBeAg -positive chronic hepatitis B.
